Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 69 of 110 Updated Nov 17, 2026

IGF-1 DES

Des(1-3) IGF-1

ANECDOTAL + ANIMAL STUDIES · IGF-1 ANALOG (TRUNCATED); ANABOLIC

▓ 25 indexed citations across PubMed (13), EuropePMC (12).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

25 citations across 1 tier

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity

Researched effects

Localized muscle hyperplasia; more potent than native IGF-1

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

50-150 mcg SC near target muscle

Known concerns

Hypoglycemia; localized tissue growth; theoretical cancer risk

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity.

    Endocrinology · 2001 — RESEARCH ARTICLES · AUTHORITY 36.1

  2. The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins.

    Endocrinology · 1996 — RESEARCH ARTICLES · AUTHORITY 36.0

  3. The direct in vitro effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins.

    Endocrinology · 1991 — RESEARCH ARTICLES · AUTHORITY 36.0

  4. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.

    2021 — RESEARCH ARTICLES · AUTHORITY 34.1

  5. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

    2016 — RESEARCH ARTICLES · AUTHORITY 33.6

  6. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.

    Oncogene · 2008 — RESEARCH ARTICLES · AUTHORITY 32.8

  7. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.

    Rapid communications in mass spectrometry : RCM · 2008 — RESEARCH ARTICLES · AUTHORITY 32.8

  8. Myogenin protein stability is decreased by BMP-2 through a mechanism implicating Id1.

    The Journal of biological chemistry · 2004 — RESEARCH ARTICLES · AUTHORITY 32.4

  9. Des(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats.

    International journal of experimental diabesity research · 2003 — RESEARCH ARTICLES · AUTHORITY 32.3

  10. Insulin-like growth factor replacement therapy for diabetic neuropathy: experimental basis.

    2003 — RESEARCH ARTICLES · AUTHORITY 32.3

Full citation library

Year distribution

Research Articles

25
  1. 1.

    Kummer A, Pulford BE, Ishii DN, Seigel GM · International journal of experimental diabesity research · 2003 · PMID 12745670

    Little is known about interventions that may prevent predegenerative changes in the diabetic retina. This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats. Type 1 IGF receptor immunoreactivity increased approximately 3-fold in both inner nuclear layer (INL) and ganglio…

  2. 2.

    Ross M, Francis GL, Szabo L, Wallace JC, et al. · The Biochemical journal · 1989 · PMID 2539101

    (1) Many cell types secrete insulin-like growth factor (IGF)-binding proteins that can be expected to sequester free IGF and modify the biological activities of the growth factors. (2) A binding protein purified from bovine kidney (MDBK) cells potently inhibited the ability of IGF-2 to stimulate DNA synthesis or protein accumulation as well as to reduce rates of protein breakdown in chick embryo fibroblasts. The binding protein did not influence the biological activities of des-(1-3)-IGF-1, whil…

  3. 3.

    Ricort JM, Binoux M · Endocrinology · 2001 · PMID 11145572

    Insulin-like growth factor binding proteins (IGFBPs) regulate the cellular actions of the IGFs owing to their strong affinities, which are equal to or stronger than the affinity of the type 1 IGF receptor (IGF-IR), the mediator of IGF signal transduction. We recently found that IGFBP-3 modulates IGF-I binding to its receptor via a different mechanism possibly involving conformational alteration of the receptor. We have now investigated the effects of IGFBP-3 on the initial steps in the IGF signa…

  4. 4.

    Guan J, Williams CE, Skinner SJ, Mallard EC, et al. · Endocrinology · 1996 · PMID 8603600

    Insulin-like growth factor (IGF)-1, IGF binding protein (IGFBP)-2, and IGFBP-3 are expressed in the rat brain in regions of neuronal loss by 3 days after hypoxic- ischemic (HI) brain injury and IGF-2 somewhat later. Central administration of rh-IGF-1 after HI injury reduces neuronal loss in vivo. To clarify the mode of action of IGF-1 and the potential role of IGFBPs, the effects of IGF-1, IGF-2, des(1-3)-N-IGF-1 (des-IGF-1), an analogue of IGF-1 with low affinity for IGFBPs, and IGF-1 combined…

  5. 5.

    Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, et al. · Oncogene · 2008 · PMID 18026134

    The insulin-like growth factor-1 (IGF-1) signaling axis is important for cell growth, differentiation and survival and increased serum IGF is a risk factor for prostate and other cancers. To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells. This encodes a mature isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid deletion in the N terminus. Expression of IGF-…

  6. 6.

    Forbes B, Szabo L, Baxter RC, Ballard FJ, et al. · Biochemical and biophysical research communications · 1988 · PMID 2973786

    Competitive binding experiments with insulin-like growth factor (IGF)-1, IGF-2 and des-(1-3)-IGF-1 have confirmed the interpretation based on limited amino-terminal sequence analysis that at least three types of IGF binding protein occur. In addition to the acid stable subunit of the large serum binding protein which exhibits des-(1-3)-IGF-1 binding only slightly less than IGF-1, the small IGF binding proteins can be separated into two classes based on differences in des-(1-3)-IGF-1 and IGF-2 bi…

  7. 7.

    Bagley CJ, May BL, Szabo L, McNamara PJ, et al. · The Biochemical journal · 1989 · PMID 2730580

    In order to elucidate the role of the N-terminus of insulin-like growth factor 1 (IGF-1) with respect to its biological properties, we chemically synthesized analogues of IGF-1 truncated by one to five amino acid residues from the N-terminus. In a bioassay that measured the stimulation of protein synthesis in rat L6 myoblasts, the concentrations required to produce a half-maximal response were: IGF-1, 13 ng/ml; des-(1)-IGF-1, 10 ng/ml; des-(1-2)-IGF-1, 13 ng/ml; des-(1-3)-IGF-1, 1.5 ng/ml; des-(…

  8. 8.

    Ballard FJ, Francis GL, Bagley CJ, Szabo L, et al. · Biochemical Society symposium · 1989 · PMID 2559737

    The insulin-like growth factors (IGFs) produce a dual anabolic effect on protein metabolism in cultured cells via a stimulus of the synthetic pathway and an inhibition of the degradative pathway. Accordingly, they offer promise as agents that may retard the extensive and life-threatening negative nitrogen balance that accompanies human polytrauma. In this report we describe the discovery of a novel, more potent, form of IGF-1, des-(1-3)-IGF-1, and explain its increased action as resulting from h…

  9. 9.

    Xu X, Mardell C, Xian CJ, Zola H, et al. · Immunology · 1995 · PMID 7558127

    It has become evident that insulin-like growth factor-1 (IGF-1) acts as a growth factor for immune cells, yet the precise regulatory role of IGF-1 in the immune system is unknown. The aim of this study was to examine the distribution of IGF-1 receptors on rat lymphoid cells. A flow cytometric method was used, with a biotinylated and functionally active IGF-1 analogue, namely des(1-3)IGF-1, which binds well to IGF-1 receptor but poorly to IGF binding proteins, followed by phycoerythrin-conjugated…

  10. 10.

    Hill DJ, Sedran RJ, Brenner SL, McDonald TJ · The Journal of endocrinology · 1997 · PMID 9135565

    We examined and compared the actions of IGF-I and -II on the release of insulin from isolated, intact rat islets of Langerhans within a perifusion system. Islets were isolated from adult male rats by collagenase digestion and Ficoll gradient separation, and were maintained in tissue culture for 48 h before perifusion. Following an equlibration period, islets were perifused with medium containing 2.7 mM glucose from 0 to 30 min. and 2.7, 11.1 or 16.7 mM glucose from 30 to 90 min. All chambers the…

  11. 11.

    Bredehöft M, Schänzer W, Thevis M · Rapid communications in mass spectrometry : RCM · 2008 · PMID 18236437

    Human insulin-like growth factor-1 (IGF-1) is a peptide hormone that acts as a mediator of most of the somatotropic effects of growth hormone (GH). Therefore, it is supposed to be a biomarker indicating GH abuse in sports as well as diseases associated with a change in IGF-1 plasma concentration. It can be applied locally by injection to increase total protein and DNA content in tissues such as skeletal muscle--a highly desirable effect in various sports disciplines. In order to improve its grow…

  12. 12.

    McGrath MF, Collier RJ, Clemmons DR, Busby WH, et al. · Endocrinology · 1991 · PMID 1713160

    Mammary epithelial cells isolated from pregnant, nonlactating heifers were grown in vitro using collagen substrates. Using these systems, the truncated form of insulin growth factor-1 (IGF-1) (des-3-IGF-1), IGF-1, and IGF-2 all stimulated a significant (0.5 to 1 fold) increase in cell proliferation (des-3-IGF-1 greater than IGF-1 greater than IGF-2). When grown in media containing serum plus IGF-1, normal bovine mammary cells also produced and secreted at least four species of IGF-binding protei…

  13. 13.

    Viñals F, Ventura F · The Journal of biological chemistry · 2004 · PMID 15322112

    Bone morphogenetic protein-2 (BMP-2) induces a switch in differentiation of mesenchymal cells from the myogenic to the osteogenic lineage. Here we describe that in C2C12 cells, BMP-2 decreases myogenin expression induced by des-(1,3) insulin-like growth factor-1 (des-(1,3)IGF-1) or ectopically expressed from a constitutive promoter, even in conditions where myogenin mRNA levels were unaffected. Addition of BMP-2 decreases myogenin protein half-life to 50%, whereas proteasome inhibitors abolish t…

  14. 14.

    Bailes J, Soloviev M. · 2021 · PMID 33557137

    Insulin-like growth factor-1 (IGF-1) is the principal mediator of growth hormone (GH), plays a crucial role in promoting cell growth and differentiation in childhood and continues to have an anabolic effect in adults. IGF-1 is part of a wide network of growth factors, receptors and binding proteins involved in mediating cellular proliferation, differentiation and apoptosis. Bioavailability of IGF-1 is affected by insulin-like growth factor binding proteins (IGFBPs) which bind IGF-1 in circulatio…

  15. 15.

    NISHIMOTO SEIO. · 2002

    PROBLEM TO BE SOLVED: To provide an agent for the prevention and treatment of Alzheimer's disease, especially familial Alzheimer's disease. SOLUTION: Insulin-like growth factor I(IGF-I), des(1-3)IGF-1, insulin-like growth factor I receptor (IGF-IR), V922E-IGF-IR, etc., can be used as an agent for the prevention and treatment of Alzheimer's disease based on the findings that IGF-I suppresses the apoptosis of Alzheimer V6421 variant APP through IGF-IR, des(1-3)IGF-I also suppresses the apoptosis i…

  16. 16.

    Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. · 1995 · PMID 7644533

    In the present study, the cardioprotective effects of insulin-like growth factor I (IGF-I) were examined in a murine model of myocardial ischemia reperfusion (i.e., 20 min + 24 hr). IGF-I (1-10 micrograms per rat) administered 1 hr prior to ischemia significantly attenuated myocardial injury (i.e., creatine kinase loss) compared to vehicle (P < 0.001). In addition, cardiac myeloperoxidase activity, an index of neutrophil accumulation, in the ischemic area was significantly attenuated by IGF-I (P…

  17. 17.

    Costales J, Kolevzon A. · 2016 · PMID 26780584

    Central nervous system (CNS) development is a finely tuned process that relies on multiple factors and intricate pathways to ensure proper neuronal differentiation, maturation, and connectivity. Disruption of this process can cause significant impairments in CNS functioning and lead to debilitating disorders that impact motor and language skills, behavior, and cognitive functioning. Recent studies focused on understanding the underlying cellular mechanisms of neurodevelopmental disorders have id…

  18. 18.

    Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Ballard FJ. · 1993 · PMID 7683875

    The effects of graded doses of insulin-like growth factor-I (IGF-I) and two variants which bind poorly to IGF-binding proteins were investigated in 160 g streptozotocin-induced diabetic rats. The two variants were the truncated form, des(1-3)IGF-I, and another with arginine at residue 3 and an N-terminal extension, termed LR3-IGF-I. The peptides were infused via mini-osmotic pumps. Reference groups received either vehicle or insulin (30 i.u. per day). Treatment led to a marked dose-dependent inc…

  19. 19.

    Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. · 1993 · PMID 7688957

    Recombinant insulin-like growth factor-II (IGF-II) and two structural analogues, des(1-6)IGF-II and [Arg6]-IGF-II, were produced to investigate the role of N-terminal residues in binding to IGF-binding proteins (IGFBPs) and hence the biological properties of the modified peptides. The growth factors were modelled on two previously characterized variants of IGF-I, des(1-3)IGF-I and [Arg3]-IGF-I, which both show substantially decreased binding to IGFBPs and were expressed as fusion proteins in Esc…

  20. 20.

    Galiano RD, Zhao LL, Clemmons DR, Roth SI, Lin X, Mustoe TA. · 1996 · PMID 8958208

    We have determined previously that IGF-I is dependent on the presence of IGF binding protein-1 (IGFBP-1) to act as a wound healing agent. We sought to determine the mechanism whereby IGFBP-1 is able to enhance IGF-I bioactivity. As IGFBP-1 binds both the alpha5beta1 integrin as well as IGF-I in vitro, we asked which of the following interactions were important: (a) the ability of IGFBP-1 to interact with an integrin receptor, and/or (b) the binding of IGF-I by IGFBP-1. We used an IGF-1 analogue…

  21. 21.

    Adashi EY, Resnick CE, Ricciarelli E, Hurwitz A, Kokia E, Tedeschi C, Botero L, Hernandez ER, Rosenfeld RG, Carlsson-Skwirut C. · 1992 · PMID 1383276

    An increasing body of information now suggests that insulin-like growth factor (IGF) binding proteins (BPs) may serve as antigonadotropins at the level of the ovary. It is the objective of the present communication to evaluate the functional role of endogenous (granulosa cell-derived) IGFBPs by exploiting the unique properties of des(1-3)IGF-I, a naturally occurring IGF-I analogue characterized as a weak ligand of IGFBPs but not of type I IGF receptors. Given IGFBP-replete circumstances, des(1-3…

  22. 22.
  23. 23.

    Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. · 1988 · PMID 3390164

    1. Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) together with a truncated form of IGF-1 were purified to homogeneity from bovine colostrum. 2. Two forms of IGF-1 were totally resolved from IGF-2 in the purification by h.p.l.c. involving cation-exchange and reverse-phase columns. 3. The complete amino acid sequences for all three forms of IGF were determined. The sequence of bovine IGF-1 was found to be identical with that of human IGF-1, and that of the variant lacked the N-terminal tri…

  24. 24.

    Ding H, Gao XL, Hirschberg R, Vadgama JV, Kopple JD. · 1996 · PMID 8613530

    The actions of insulin-like growth factor 1 (IGF-1) on protein turnover and of the IGF-1 receptor (IGF-1R) were examined in skeletal muscle of rats with chronic renal failure (CRF) and sham operated (SO), pair-fed controls. Acidemia was prevented in CRF rats with NaHCO3. Serum IGF-1 and skeletal muscle IGF-1 and IGF-1 mRNA were reduced in CRF rats. Dose-response studies revealed impaired stimulation of protein synthesis and suppressed inhibition of protein degradation by IGF-1 in epitrochlearis…

  25. 25.

Curated sources on file

2
  1. 1.
  2. 2.

Continue reading